To describe the development of a novel treatment for food allergy, named the food allergy herbal formula-2 (FAHF-2), that is based on traditional Chinese medicine.
INTRODUCTION
Food allergy continues to be a public health concern, now affecting up to 8% of children and 3% of adults [1, 2] . The eight food allergens accounting for the majority of reactions are milk, egg, wheat, soy, peanut, tree nuts, fish, and shellfish [3] . Whereas some allergies such as milk and egg are often transient, allergies to peanut, tree nuts, fish, and shellfish are often lifelong. The current standard of care is the avoidance of food allergens and preparedness for potentially life-threatening allergic reactions. Although there are obvious medical concerns related to food allergy management, the impact of food allergies reaches beyond the affected individual, extending into social, public health (schools, restaurants, etc.), and economic realms as well. Thus, there are many compelling reasons to develop effective treatments or cures for food allergy.
In recent years, there has been growing interest in using complementary or alternative approaches in the management of various medical disorders. The 2007 National Health Interview Survey (NHIS) study [4] reported that 38% of adults and 12% of children had used complementary or alternative medicine (CAM) in the last year, with the annual expenditure for CAM exceeding $30 billion. In fact, Eisenberg et al. [5] found that many people spend far more money on CAM-related techniques or supplies than they are willing to spend on physician visits or western medications.
Traditional Chinese medicine (TCM) has been used in China and other Asian countries for thousands of years, either as monotherapy or in combination with standard Western medical treatment, to manage the entire spectrum of medical disorders. One component of TCM is herbal therapy, and the main principal underlying the use of herbal formulas is that complex interactions between herbs produce synergistic effects that can reduce possible side-effects of individual herbs. Although food allergy has not been a prominent issue in Eastern countries and therefore is not a disorder that can be searched for in TCM texts, parasitic illnesses with symptoms similar to those seen in food-induced anaphylaxis can be found in the TCM literature [6] . Thus, the strong desire to develop treatments for food allergy combined with growing interest in using novel or alternative approaches to treatment led to the exploration of TCM as a possible novel therapy for food allergies.
Wu-Mei Wan is a 10-herb classical formula used for the treatment of intestinal parasite infections [6] . It was first documented in a classical Chinese medical textbook compiled some 2000 years ago. The indication for use of this has many similarities with the symptoms of anaphylaxis. Wu-Mei Wan has also been demonstrated to be effective for gastroenteritis and asthma in Chinese clinical studies [7] . In the development of a formula for food allergy, an additional herb was included, Ling Zhi, which has shown to have antiallergy and anti-inflammatory properties [8, 9] . This 11-herb formula was named the food allergy herbal formula-1 (FAHF-1) [10] . Subsequently, two herbs (Xi-Xin and Zhi-Fu-Zi) were removed from the formula to improve the safety profile as these two herbs are potentially toxic if processed improperly. The resulting nine-herb formula, named the food allergy herbal formula-2 (FAHF-2), is used for the murine and clinical studies [11] .
The components of FAHF-2 are shown in Table 1 . Ling Zhi and Wu Mei comprise the largest part of FAHF-2.
FOOD ALLERGY HERBAL FORMULA-2 EFFECTS IN MURINE MODELS OF FOOD-INDUCED ANAPHYLAXIS
The high safety profile of FAHF-2 was demonstrated in an experiment in which mice were fed 24 times the effective daily dose [11] . These mice exhibited no signs of acute toxicity and all appeared healthy 2 weeks after the dose. Results for complete blood counts and biochemical assays for renal and hepatic function were within the normal range, and no abnormalities were seen on histology of the major organs (kidney, liver, heart, spleen, lung, stomach, and intestines).
The efficacy of FAHF-2 was tested using a murine model of peanut anaphylaxis. C3H/HeJ mice were sensitized with peanut and cholera toxin as previously described [11] . FAHF-2 treatment was administered orally twice a day for 7 weeks. This dose was based on a version of the equivalent KEY POINTS FAHF-2 treatment in peanut allergic mice results in protection from peanut-induced anaphylaxis that persists for approximately 6 months.
In the murine model, protection from anaphylaxis is associated with decreased allergen-specific IgE, increased IgG2a, decreased Th2 cytokines production, and increased IFN-gamma production.
Given the high safety profile and effectiveness in the murine model, clinical trials in humans are underway. Phase I clinical trials demonstrated the safety of FAHF-2 in food allergic individuals, and a Phase II study investigating the efficacy is ongoing.
Studies are ongoing to identify the active compounds and elucidate the mechanisms of action of this herbal formula. effective daily dose from humans to the mouse based on body surface area. Posttreatment challenges showed that FAHF-2treated mice were protected from peanut-induced anaphylaxis, with symptom scores, body temperatures, and plasma histamine levels demonstrating lack of allergic reaction, similar to naïve mice. In contrast, sham-treated mice had severe, near-fatal reactions, significant drops in body temperature, and elevated plasma histamine levels with each of the peanut challenges. The FAHF-2-treated group was protected from anaphylaxis for nearly 6 months, and the effect was present both when FAHF-2 was administered early in the peanut sensitization process and when treatment was given after peanut allergy had been established [12, 13] . Treatment effect appeared to wane after approximately 6 months; however, a second course of treatment with FAHF-2 re-established the protection from peanut-induced anaphylaxis.
In addition to the clinical parameters, significantly decreased peanut-specific IgE was seen in the FAHF-2 treated mice by the fourth week of treatment (week 12). Peanut-specific IgE remained lower in the FAHF-2 treated group even after discontinuation of treatment; this effect paralleled the clinical effects and was evident through week 50 ( Fig. 1 ). Peanutspecific IgG2a levels were conversely significantly elevated by the fourth week of treatment and continued to be elevated through week 50.
In addition, sustained modulation of cytokines was seen at week 50 with significant reductions in the production of Th2 cytokines, IL-4, IL-5, and IL-13 by the cells of mesenteric lymph node and splenocytes. Enhanced production of interferongamma was seen, demonstrating that skewing of the immune system rather than immunosuppression is at play. Interferon-gamma has been shown to contribute to the downregulation of Th2 cytokines and reduction of IgE production, and thus appears to be one of the mechanisms by which FAHF-2 mediates protection from peanut-induced anaphylaxis in the murine model of peanut allergy [14, 15] .
To further elucidate the potential mechanisms of action of FAHF-2, effects on mast cell and basophils were investigated [16] . A reduction in peripheral blood basophils and peritoneal mast cells was seen, as well as a decrease in mast cell FceRI expression; however, basophil FceRI expression was unaffected. In-vitro effects of FAHF-2 on a murine mast cell line (MC/9 cells) showed inhibition of IgE-mediated proliferation and degranulation (using anti-DNP IgE). These findings indicate that FAHF-2 directly suppresses basophil and mast cell activities.
Using a murine model of multiple food allergies (to peanut, egg, and fish), FAHF-2 proves to be food allergen nonspecific, suggesting potential clinical applications for all food allergic individuals. Similarly to earlier experiments, the same dose of FAHF-2 was administered twice a day for 7 days after the mice had been sensitized and boosted to all three allergens [17 && ]. Posttreatment challenges for peanut, egg, and codfish showed protection from anaphylaxis as evidenced by lack of symptoms, lack of change in body temperature, no change in plasma histamine level after each of the food challenges. Reduction in allergen-specific IgE and increased specific IgG2a levels were seen, along with significant decreases in Th2 cytokine production and increased IFN-gamma production by splenocytes and mesenteric lymph node cells. 
CLINICAL TRIALS
On the basis of the promising results from the murine models demonstrating effective and durable protection from anaphylaxis and favorable immunomodulation, FDA approval of FAHF-2 as an investigational new drug was obtained in 2007 (IND 77 468). The first steps in clinical development of this formula were standardization of the raw herbs, manufacturing process, and final product. All herbs originate from China and are inspected by licensed pharmacists to ensure the identity and quality of the herbs [18] . Extensive safety data testing is performed, including limit testing of pesticides, heavy metals, and microbials. Although the traditional method for administering herbal medicines is in the form of decoctions to be taken orally, FAHF-2 is produced in tablet form, which is more acceptable to Western palates and more conducive for use in clinical trials. Consistency of the final product is assessed with HPLC fingerprinting. The first clinical trial was a double-blind, placebo-controlled, dose-escalation trial (acute Phase I trial) [18] . Individuals between 12 and 45 years of age who had documented peanut, tree nut, fish, and/or shellfish allergy (based on history and positive skin test and/or detectable food-specific IgE) were enrolled. Individuals took 4, 6, or 12 tablets three times a day for 7 days. FAHF-2 was well tolerated, with no significant adverse effects seen (clinical report, laboratory parameters measuring complete blood count and complete metabolic profile, urinalysis, electrocardiogram, and pulmonary function tests). Although not a primary endpoint of the study, laboratory studies were performed to assess for the early indications of immunologic effect. Ex-vivo effects of FAHF-2 on cytokine levels in peripheral blood mononuclear cells (PBMCs) from patients before and after FAHF-2 treatment showed significant decrease in IL-5 production by PBMCs from the treated group that was not seen in the placebo group. No other immunologic changes were seen after this short course of treatment.
As TCM herbal formulas are generally prescribed for chronic use, the long-term safety and tolerability of FAHF-2 were assessed in an extended phase I trial [19] . In this open-label study, individuals received six tablets of FAHF-2 three times a day for 6 months. A total of 18 individuals were enrolled and 14 individuals completed the treatment. Four individuals withdrew from the trial: two individuals had difficulties with time commitment and adherence, one with transient abdominal complaints without vomiting or diarrhea, and one because of pregnancy. Results of this study demonstrated that prolonged treatment with FAHF-2 was well tolerated, with no significant adverse effects. Some evidence of favorable immunomodulatory effects were also seen in this small sample of patients. Suppression of allergen-stimulated basophil activation (CD63 expression) was seen after 6 months. There was also a trend toward reduction in peripheral blood basophil and eosinophil percentages after 6 months of FAHF-2 treatment.
Currently, a phase II clinical trial is ongoing to assess the efficacy of FAHF-2 for the treatment of food allergies. A total of 68 individuals, age 12-45 years, with peanut, tree nut, sesame, fish, or shellfish allergy have been enrolled at three sites in this randomized double-blind, placebo controlled study. Individuals are randomized to receive 10 tablets of FAHF-2 or placebo 3 times a day for 6 months (2 : 1 FAHF-2 : placebo). The primary outcome is the change in the threshold dose of allergen to induce a reaction during a double-blind, placebocontrolled oral food challenge. Secondary outcomes include changes in skin prick test sizes, allergenspecific IgE and IgG4 levels, epitope recognition using peptide microarray immunoassay, basophil activation, and T-cell activity.
FUTURE DIRECTIONS
The daily dose of FAHF-2 is large, making it a difficult treatment regimen to adhere to for long periods of time. Several strategies for reducing this daily dose have been explored, including reducing the number of components in the formula, alternate methods of extraction, and identification and isolation of active compounds.
In a series of experiments using the murine model of peanut allergy, the relative effectiveness of each individual herb was examined for both clinical and laboratory parameters [20] . No individual herb was as effective as the FAHF-2 formula at protecting the mice from peanut-induced anaphylaxis, suppressing peanut-specific IgE, and increasing peanut-specific IgG2a. Although a few herbs did provide protection in some mice for some parameters, the effect was not consistent across all parameters measured. For example, although Huang-Bai showed some efficacy at protecting some mice from the symptoms of anaphylaxis, treatment with this herb did not result in any changes in peanut-specific IgE or IgG2a. A simplified formula of three herbs (Huang-Bai, Ling Zhi, and Gan-Jiang) that were most effective in reducing the symptoms of anaphylaxis and/or Th2 cytokine production also did not achieve the same level of effectiveness as the FAHF-2 formula. These results indicate that the efficacy of FAHF-2 probably rests on the synergy of all nine herbs, which are necessary to provide complete and durable protection against anaphylaxis and the associated immunomodulatory effects.
A refined FAHF-2 has been developed using an additional butanol purification step (B-FAHF-2) [21] . In the murine model, B-FAHF-2 at one-fifth the dose of FAHF-2 confers a similar level of protection from peanut-induced anaphylaxis. Similarly to the original formula, B-FAHF-2-treated mice have no symptoms of allergy upon challenge with peanut, are able to maintain their body temperatures, and lack elevations in plasma histamine levels. These effects are durable, lasting up to 6 months. Immunologic effects are also consistent with the original formula. There is suppression of peanutspecific IgE and enhancement of peanut-specific IgG2a. Th2 cytokine production (IL-4, IL-5, and IL-13) by splenocytes and mesenteric lymph nodes are decreased, but interferon-gamma production is increased in treated mice. Consistently with the original formula, re-treatment with a second course of B-FAHF-2 re-establishes protection after treatment effects wane. Furthermore, the safety profile of B-FAHF-2 is similar to FAHF-2.
Ongoing efforts to identify the active compounds have focused on fractionating the FAHF-2 based on polarity using preparative HPLC. The effects of these fractions were first tested on the RBL-2H3 cell line as an in-vitro model, using the b-hexosaminidase assay to assess impact on mast cell degranulation. The fraction that contained primarily alkaloid compounds (fraction 2) significantly reduced b-hexosaminidase release [16] . Similar results were seen for the alkaloid fraction using human skin mast cells. Using liquid chromatography mass spectrometry, the three major alkaloid components of this fraction were identified to be berberine, palmatine, and jatrorrhizine. These individual compounds inhibited mast cell degranulation in RBL-2H3 cells in a nontoxic, dose-dependent manner and the combined effects significantly inhibited Syk phosphorylation, but none of these compounds inhibited IgE binding to mast cells. Additional studies using cultured macrophages (RAW264.7) and human B-cells (U266 human myeloma cells) demonstrated that the same three alkaloids (berberine, palmatine, and jatrorrhizine) showed strong inhibition of B-cell IgE production [22] . Further studies to identify the key players within FAHF-2 will lead to a better understanding of the mechanism of action of the formula and hopefully lead to refined dosing strategies.
CONCLUSION
Results from both murine experiments and early clinical trials suggest that FAHF-2 may be an effective approach to food allergy treatment that is not specific to any one food allergen and can be potentially used to treat multiple food allergies. The ongoing Phase II clinical trial should yield much anticipated information regarding the effects of this formula on human food allergies.
